Nektar Therapeutics | NKTR - 应收帐款人



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 10.9B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


应收帐款人 更改 日
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
ALKERMES USD 407.63M 73.6M 2026-03
Alterity Therapeutics Limited AUD 4.57M 1.42M 2025-12
Amgen USD 9.14B 432M 2026-03
Baxter International USD 1.7B 310M 2026-03
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Cara Therapeutics USD 2.24M 2.26M 2025-03
Cipla INR 62.19B 12.42B 2026-03
Dr.Reddys Laboratories INR 104.74B 563M 2026-03
Eisai JPY 227B 22.05B 2026-03
Eli Lilly USD 21.18B 1.02B 2026-03
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Exelixis USD 328.95M 42.03M 2026-03
Gilead Sciences USD 4.74B 172M 2026-03
GlaxoSmithKline GBP 7.94B 178M 2026-03
Grifols EUR 1B 285.88M 2025-12
Halozyme Therapeutics USD 457.99M 16.72M 2026-03
Incyte USD 1.05B 27.09M 2026-03
Ionis Pharmaceuticals USD 74M 8M 2026-03
Ironwood Pharmaceuticals USD 81.89M 5.68M 2024-12
Karyopharm Therapeutics USD 26.18M 5.6M 2025-12
MacroGenics USD 13.37M 55.86M 2025-12
Merck USD 11.78B 345M 2025-12
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
Novartis USD 9.6B 2.69B 2026-03
Pfizer USD 16.17B 332M 2026-03
Roche Holding CHF 11.9B 460M 2025-12
Sarepta Therapeutics USD 547.91M 149.68M 2026-03
Takeda JPY 876.35B 118.43B 2026-03
Teva Pharmaceutical Industries USD 3.39B 316M 2026-03
Xencor USD 12M 17.3M 2026-03